Skip to Content
Merck
CN
  • Blood donors on teratogenic drugs and donor deferral periods in a clinical situation.

Blood donors on teratogenic drugs and donor deferral periods in a clinical situation.

Vox sanguinis (2012-01-04)
S Y Shin, Y H Shin, S W Lee, J Y Shin, C H Kim
ABSTRACT

Deferral of blood donors taking teratogenic drugs is critical. From March 2008 to January 2009, we analysed stored blood specimens from donors who had taken teratogenic drugs and whose blood was transfused to women of childbearing age to determine the plasma concentration at the time of donation using high-performance liquid chromatography. In total, 167 specimens were examined. The numbers of specimens exceeding the quantification limit were 7, 39, 4, 2 and 1 for finasteride, isotretinoin, acitretin, etretinate and dutasteride, respectively. Finasteride was beyond the recommended drug deferral period in one specimen. These results may help create practical deferral policies.

MATERIALS
Product Number
Brand
Product Description

USP
Acitretin Related Compound B, United States Pharmacopeia (USP) Reference Standard